ZAI LAB LTD (ZLAB)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$22.07-1.30%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put ZLAB beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Reduce operating losses and improve operating income over time: Comparison needs review.
View ThesisRevenue growth is slowing — up about 5% over the past year and decelerating.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, margins.
View ManagementExpectations look high — the market is pricing in about 301% growth a year, above the roughly 12% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 39% in its worst 12-month stretch.
View RiskZai Lab depends on restoring revenue growth and reducing operating losses, though growth currently runs backward. Q2 FY2026 revenue fell 3% year over year, and GAAP EPS was negative. The latest recorded quarter has no earnings verdict, and no earnings release is on record. ZLAB trades at 56× sales versus a 10× peer median, near its 58× historical multiple. That premium assumes growth beyond our forecast, while the market prices in more growth than we forecast. Our model puts the next-quarter miss probability near 40%. The operating-loss pillar is under review, so its comparison remains unverified. Peer multiples imply a price about 301% below where it trades. This read is provisional.
Trailing returns as of 2026-10-30. ZLAB is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 12 analysts currently covering ZLAB (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare ZLAB with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ZLAB Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 2 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put ZLAB next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Manage cash flow and maintain strong liquidity
Official financing may strengthen liquidity, though dilution and use of proceeds determine net thesis impact.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Manage cash flow and maintain strong liquidity
Reported placement may support liquidity; dilution and use of proceeds determine net thesis impact.
Advances: Manage cash flow and maintain strong liquidity
Reported $250 million financing supports liquidity, though dilution and financing terms may offset some benefit.
Advances: Advance global oncology and immunology pipeline
Positive phase 3 data supports oncology pipeline advancement.
Advances: Advance global oncology and immunology pipeline
Positive phase 3 data supports oncology pipeline advancement.
Leadership changes may disrupt strategic execution and revenue growth.
Senior leadership changes could impact operational focus and income.